Cargando…

Immunity following intranasal administration of an inactivated, freeze-dried A/England/42/72 vaccine

A group of 23 student volunteers were each inoculated intranasally with 400 IU of inactivated, freeze-dried A/England/42/72 vaccine. Only one volunteer showed a four-fold rise in serum HI antibody following immunization, and the mean increase in serum HI antibody (gmt) for all volunteers did not inc...

Descripción completa

Detalles Bibliográficos
Autores principales: Potter, C. W., Jennings, R., McLaren, C., Clarke, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 1975
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102198/
https://www.ncbi.nlm.nih.gov/pubmed/1200844
http://dx.doi.org/10.1007/BF01317429
_version_ 1783511768489787392
author Potter, C. W.
Jennings, R.
McLaren, C.
Clarke, A.
author_facet Potter, C. W.
Jennings, R.
McLaren, C.
Clarke, A.
author_sort Potter, C. W.
collection PubMed
description A group of 23 student volunteers were each inoculated intranasally with 400 IU of inactivated, freeze-dried A/England/42/72 vaccine. Only one volunteer showed a four-fold rise in serum HI antibody following immunization, and the mean increase in serum HI antibody (gmt) for all volunteers did not increase two-fold. Thirteen of the volunteers developed detectable levels of nasal wash neutralizing antibody after immunization; local antibody was most commonly found in volunteers who also produced a detectable but less than four-fold rise in serum antibody titre, and who produced nasal washings with relatively high concentrations of protein and secretory IgA. Four weeks after immunization, the vaccinees and a matched group of control subjects were inoculated with attenuated A/England/42/72 (MRC-7) virus. Evidence of infection was found in 14 of 23 (61 per cent) of control subjects and in seven of 23 (30 per cent) of immunized volunteers. This result showed a significant protection (P=0.04) against challenge virus infection for volunteers given intranasal vaccine.
format Online
Article
Text
id pubmed-7102198
institution National Center for Biotechnology Information
language English
publishDate 1975
publisher Springer-Verlag
record_format MEDLINE/PubMed
spelling pubmed-71021982020-03-31 Immunity following intranasal administration of an inactivated, freeze-dried A/England/42/72 vaccine Potter, C. W. Jennings, R. McLaren, C. Clarke, A. Arch Virol Article A group of 23 student volunteers were each inoculated intranasally with 400 IU of inactivated, freeze-dried A/England/42/72 vaccine. Only one volunteer showed a four-fold rise in serum HI antibody following immunization, and the mean increase in serum HI antibody (gmt) for all volunteers did not increase two-fold. Thirteen of the volunteers developed detectable levels of nasal wash neutralizing antibody after immunization; local antibody was most commonly found in volunteers who also produced a detectable but less than four-fold rise in serum antibody titre, and who produced nasal washings with relatively high concentrations of protein and secretory IgA. Four weeks after immunization, the vaccinees and a matched group of control subjects were inoculated with attenuated A/England/42/72 (MRC-7) virus. Evidence of infection was found in 14 of 23 (61 per cent) of control subjects and in seven of 23 (30 per cent) of immunized volunteers. This result showed a significant protection (P=0.04) against challenge virus infection for volunteers given intranasal vaccine. Springer-Verlag 1975 /pmc/articles/PMC7102198/ /pubmed/1200844 http://dx.doi.org/10.1007/BF01317429 Text en © Springer-Verlag 1975 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Potter, C. W.
Jennings, R.
McLaren, C.
Clarke, A.
Immunity following intranasal administration of an inactivated, freeze-dried A/England/42/72 vaccine
title Immunity following intranasal administration of an inactivated, freeze-dried A/England/42/72 vaccine
title_full Immunity following intranasal administration of an inactivated, freeze-dried A/England/42/72 vaccine
title_fullStr Immunity following intranasal administration of an inactivated, freeze-dried A/England/42/72 vaccine
title_full_unstemmed Immunity following intranasal administration of an inactivated, freeze-dried A/England/42/72 vaccine
title_short Immunity following intranasal administration of an inactivated, freeze-dried A/England/42/72 vaccine
title_sort immunity following intranasal administration of an inactivated, freeze-dried a/england/42/72 vaccine
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102198/
https://www.ncbi.nlm.nih.gov/pubmed/1200844
http://dx.doi.org/10.1007/BF01317429
work_keys_str_mv AT pottercw immunityfollowingintranasaladministrationofaninactivatedfreezedriedaengland4272vaccine
AT jenningsr immunityfollowingintranasaladministrationofaninactivatedfreezedriedaengland4272vaccine
AT mclarenc immunityfollowingintranasaladministrationofaninactivatedfreezedriedaengland4272vaccine
AT clarkea immunityfollowingintranasaladministrationofaninactivatedfreezedriedaengland4272vaccine